Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drugresistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6242-6250

  De Kock, Lizanne ^a   Sy, Sherwin K B ^b   Rosenkranz, Bernd ^a   Diacon, Andreas H ^a   Prescott, Kim ^a   Hernandez, Kenneth R ^b   Yu, Mingming ^b   Derendorf, Hartmut ^b   Donald, Peter R ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ZIDOVUDINE; BENZOXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MONTE CARLO METHOD; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADULT; AMINOSALICYLIC ACID; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; CROSS-OVER STUDIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84907907883     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03073-14     Document Type: Article

References (54)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021. http://dx.doi.org/10.1001/archinte.163.9.1009 .
2. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I. 2011. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365:1482-1491. http://dx.doi.org/10.1056/NEJMoa1013607 .
3. Cox H, Ford N, McDermid C, van Cutsem G, Goemaere E. 2010. Extensively drug-resistant tuberculosis in South Africa. Lancet 376:681. http://dx.doi.org/10.1016/S0140-6736(10)61327-X .
4. Cox HS, McDermid C, Azevedo V, Muller O, Coetzee D, Simpson J, Barnard M, Coetzee G, van Cutsem G, Goemaere E. 2010. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 5:el3901. http://dx.doi.org/10.1371/joumal.pone.0013901 .
5. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH. 2010. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am. J. Respir. Crit. Care Med. 181:80-86. http://dx.doi.org/10.1164/rccm.200907-0989OC .
6. Raviglione MC, Smith IM. 2007. XDR tuberculosis-implications for global public health. N. Engl. J. Med. 356:656-659. http://dx.doi.org/10.1056/NEJMp068273 .
7. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE. 2001. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann. Pharmacother. 35:1332-1338. http://dx.doi.org/10.1345/aph . 1A088.
8. Berte SJ, Dewlett HJ. 1959. Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS. Dis. Chest 36:146-151. http://dx.doi.org/10.1378/chest.36.2.146 .
9. Heifets LB. 1991. Antituberculosis drugs: antimicrobial activity in vitro, p 13-58. In Heifets LB (ed), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.
10. Fox W, Sutherland I. 1956. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q. J. Med. 25: 221-243.
11. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS. 2012. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int. J. Tuberc. Lung Dis. 16:90-97. http://dx.doi.org/10.5588/ijtid.ll.0153 .
12. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. 1999. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am. J. Respir. Crit. Care Med. 159:932-934.
13. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. 1994. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 14:40-46.
14. Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR. 2013. Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. J. Trop. Pediatr. 59:90-94. http://dx.doi.org/10.1093/tropej/fins053 .
15. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. http://dx.doi.org/10.1007/sl0928-007-9066-0 .
16. Upton RN, Mould DR. 2014. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 3:e88. http://dx.doi.org/10.1038/psp.2013.71 .
17. Bulitta JB, Landersdorfer CB, Kinzig M, Holzgrabe U, Sorgel F. 2009. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Antimicrob. Agents Chemother. 53:3462-3471. http://dx.doi.org/10.1128/AAC.00054-09 .
18. Vong C, Bergstrand M, Nyberg J, Karlsson MO. 2012. Rapid sample size calculations for a defined likelihood ratio test-based power in mixedeffects models. AAPS J. 14:176-186. http://dx.doi.org/10.1208/s12248-012-9327-8 .
19. Way EL, Smith PK, Howie DL, Weiss R, Swanson R. 1948. The absorption, distribution, excretion and fate of para-aminosalicylic acid. J. Pharmacol. Exp. Ther. 93:368-382.
20. Bastian I, Portaeis F. 2000. Multidrug-resistant tuberculosis. Kluwer, Dordrecht, The Netherlands.
21. World Health Organization. Guidelines for programmatic management of drug-resistant tuberculosis. WHP/HTM/TB/2008.402. World Health Organization, Geneva, Switzerland.
22. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. 2002. Hepatic but not intestinal CYP3A4 displays dosedependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72: 1-9. http://dx.doi.org/10.1067/mcp.2002.124519 .
23. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. 2013. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J. Biol. Chem. 288:23447-23456. http://dx.doi.org/10.1074/jbc.M113.475798 .
24. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-20026215000001 .
25. Hong L, Jiang W, Zheng W, Zeng S. 2011. HPLC analysis of paraaminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues. J. Pharm. Biomed. Anal. 54:1101-1109. http://dx.doi.org/10.1016/j.jpba.2010.11.031 .
26. Cummins CL, O'Neil WM, Soo EC, Lloyd DK, Wainer IW. 1997. Determination of p-aminosalicylic acid and its N-acetylated metabolite in human urine by capillary zone electrophoresis as a measure of in vivo N-acetyltransferase 1 activity. J. Chromatogr. B Biomed. Sci. Appl. 697: 283-288. http://dx.doi.org/10.1016/S037S-4347(97)00084-4 .
27. Wan SH, Pentikainen PJ, Azarnoff DL. 1974. Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J. Pharm. Sci. 63:708-711.
28. Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart DA, Desta Z. 2014. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics J. 14:151-159. http: //dx.doi.org/10.1038/tpj,2013,17.
29. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. 2013. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob. Agents Chemother. 57:2780-2787. http://dx.doi.org/10.1128/AAC.00191-13 .
30. Lee LS, Pham P, Flexner C. 2012. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by efavirenz. Ann. Acad. Med. Singapore 41: 559-562.
31. Turpeinen M, Zanger UM. 2012. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metab. Drug Interact. 27:185-197.
32. Habtewold A, Amogne W, Makonnen E, Yimer G, Nylen H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E. 2013. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J. 13:484-489. http://dx.doi.org/10.1038/tpj.2012.46 .
33. Ji HY, Lee H, Lim SR, Kim JH, Lee HS. 2012. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules 17:851-860. http://dx.doi.org/10.3390/molecules17010851.
34. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E. 2011. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin. Pharmacol. Ther. 90:406-413. http://dx.doi.org/10.1038> /clpt.2011.129.
35. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44: 1273-1281. http://dx.doi.org/10.1177/0091270004269142 .
36. Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H. 2000. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-318. http://dx.doi.org/10.1086/313667 .
37. Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M, Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM. 2002. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 71:57-67. http://dx.doi.org/i0.1067/mcp.2002.323424 .
38. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. 2001. The pharmacokinetics of methadone in HIV-positive pa-tients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51:213-217. http://dx.doi.Org/10.1046/j.13652125.2001.00342.x .
39. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E. 2011. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 6:e27810. http://dx.doi.org/10.1371/journal.pone.0027830 .
40. McIlleron H, Meintjes G, Burman WJ, Maartens G. 2007. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196(Suppl 1):S63-S75. http://dx.doi.org/10.1086/518655 .
41. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137:381-433. http://dx.doi.org/10.7326/0003-4819-137-5> .,Part .,2-200209031-00001.
42. Berning SE, Peloquin CA. 1998. Antimycobacterial agents: paraaminosalicylic acid, p 663-668. In Yu VL, Merigan TC, Barriere S, White NJ (ed), Antimicrobial chemotherapy. Williams and Wilkins, Baltimore, MD.
43. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. 2003. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662. http://dx.doi.Org/10.1164/rccm.167.4.603 .
44. Bridge EV, Carr DT. 1958. Clinical use of a single daily dose of paraaminosalicylic acid in association with isoniazid. Am. Rev. Tuberc. 78: 749-752.
45. Riska N, Tennberg C. 1962. Optimal PAS dosage. Am. Rev. Respir. Dis. 86:430-433.
46. Lehmann J. 1969. The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand. J. Respir. Dis. 50:169-185.
47. Karslon AG, Carr DT. 1958. Effect of single and of double daily doses of para-aminosalicylic acid in tuberculosis of guinea pigs. Am. Rev. Tuberc. 78:753-759.
48. Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
49. British Medical Journal. 1952. Prevention of streptomycin resistance by combined chemotherapy. Br Med. J. 1:1157-1162. http://dx.doi.org/10.1136/bmj.1.4769.1157 .
50. British Medical Journal. 1953. Isoniazid in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis. Br Med. J. 2:1005-1014. http://dx.doi.Org/10.1136/bmj.2.4844.I005 .
51. Singh B, Mitchison DA. 1955. Bactericidal activity of streptomycin and isoniazid in combination with p-aminosalicylic acid against Mycobacterium tuberculosis. J. Gen. Microbiol. 12:76-84. http://dx.doi.org/10.1099/00221287-12-1-76 .
52. Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN, Bifani P. 2009. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:2100-2109. http://dx.doi.org/10.3328/AAC.01197-08 .
53. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol. 53:275-282. http://dx.doi.Org/10.1111/j.1365-2958.2004.04120.x .
54. Mitchison D. 1973. Plasma concentrations of isoniazid in the treatment of tuberculosis, p 171-182. In Davies D, Pritchard B (ed), Biological effects of drugs in relation to their plasma concentrations. Macmillan, London, United Kingdom.